Recover burn ointment for managing acute radiodermatitis in patients with breast cancer: A double blind randomized controlled trial

• Main Authors: Nargeuss Abbaszade Marzbali (Author), Ebrahim Zabihi (Author), Nicolas Magne (Author), Alexis Vallard (Author), Mohammad Moslemi (Author), Dariush Moslemi (Author)
• Format: Book
• Published: Babol University of Medical Sciences, 2022-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 2008-6164; 2008-6172
• Keywords: breast cancer; radiotherapy; radiodermatitis; recove ointment; radiation therapy oncology group.; Internal medicine; RC31-1245
• Source: Caspian Journal of Internal Medicine, Vol 13, Iss 2, Pp 349-355 (2022)

Background: Radiodermatitis is the most common complication of radiotherapy. There is no gold standard for managing the radiodermatitis. This study aimed to evaluate the effect of topical Recove® burn ointment; basically compounded of sesame oil, camphor, and zinc oxide; in preventing acute radiodermatitis. Methods: This double blind RCT (IRCT No.: 201204047136N2) was performed on 71 patients that referred for radiotherapy after mastectomy to Shahid Rajaee Hospital (Babolsar-Iran) during 2013-2017. Patients were allocated into 2 groups; 34 in control group and 37 in Recove® group. Patients applied the ointment 2 times a day, before every radiation therapy session for 5 weeks. The radiation oncologist assessed the severity of dermatitis weekly for 5 weeks and graded it from 0 to 4 according to the RTOG criteria. Results:Baseline characteristics including age, and BMI had no significant difference between groups. The Recover group patients experienced significantly less severe dermatitis compared to the controls (p<0.001). None of the patients in Recove® group encountered more than grade 2 of RTOG criteria, however, in the control group, 4 (12.9%)patients experienced grade 3 of RTOG and 3 (9.7%)patients developed grade 4 of RTOG at the end of the 5th week. Conclusion: Our results indicate that Recove® ointment significantly reduces the severity of acute radiodermatitis.